Timeline of Omicron development

- On Nov 24^th, South Africa reported to the World Health Organization (WHO) the variant B.1.1.529 for the first time, which was found related to the soaring cases in the country that month.

- On Nov 26^th, WHO held an emergency meeting to discuss the impact of B.1.1.529, and swiftly designated it Omicron, the fifth variant of concern (VOC).

- On Dec 8^th, WHO announced the variant had been detected in 57 countries.

- On Dec 13^th, the first death of a person with Omicron was reported in the UK.

Diagnosis of Omicron

In response to the continued emergence of new variants of SARS-CoV-2, the Food and Drug Administration (FDA) has revised the EUAs of certain molecular, antigen, and serology tests to establish additional Conditions of Authorization on Sep 23rd, 2021. The revision requires test developers to update their authorized labeling and evaluate the impact of SARS-CoV-2 viral mutations on their test's performance. If potential impacts are identified, the EUA holder must communicate with the FDA and end users about the potential risk that the presence of the mutations may have on test performance. Due to the astonishing number of mutations, the impact of Omicron on current diagnostic reagents are highly concerned.

Molecular tests:

Deletion of amino acids HV69-70 within the spike gene of Omicron can result in an undetectable S-gene target (S-gene target failure, SGTF) for some real-time reverse transcriptase polymerase chain reaction (RT-PCR) testing methods, which makes it highly predictive of Omicron. With the emergence of Omicron, a rapid increase in the proportion of SARS-CoV-2 samples with SGTF has been identified and the data is collected for analysis of Omicron’s estimated growth rate. However, latest reports have found a few sub-lineages of Omicron that evolved to miss the SGTF marker, which might compromise the detection efficiency by conventional PCR methods.

Antigen test:

Antigen tests is an important complement to molecular tests in screening of SARS-CoV-2 variants. Antigen detection methods that can efficiently detect Omicron mutant strains will play a critical role to meet the global need for detection, prevention and control of Omicron.

Antibody tests:

With the increasing coverage of immunization either through natural infection or vaccination, the significance of serological antibody tests has also become prominent. Tests that detect antibodies (for example, IgM, IgG) to the SARS-CoV-2 virus is a direct and reliable way to evaluate the degree of herd immunity in a population.

Highly sensitive N antibody pair ensure efficient detection of Omicron antigens

Verification with the colloidal gold platform shows that our SARS-CoV-2 nucleocapsid antibody pair (Cat. No. NUN-S95/NUN-M223) can detect the Omicron mutant strain with high accuracy and sensitivity. The detection limit of Omicron is consistent as it of the wild type (0.39 ng/mL), ensuring uncompromised detection efficiency of antigen test products developed based on this pair of antibodies.

In addition, Historical data has validated the superior performance of SARS-CoV-2 nucleocapsid antibody pair (Cat. No. NUN-S95/NUN-M223) in sandwich ELISA and lateral flow assays (LFA).

Given its verified high sensitivity and high specificity, the antibody pair is ideal for establishing a rapid antigen detection method that is critical for the prevention and control of Omicron spread.

Highly quality antigens aid the development of Omicron antibody detection tools

ACROBiosystems has now developed all necessary antigen proteins required for the development of Omicron detection tests, including full-length spike trimer, S RBD, NTD, S1, and Nucleocapsid protein.

As the world's leading supplier of protein reagents for COVID-19 diagnostic tests, ACRO is committed to developing high-quality products and technologies to address the urgent needs of the IVD industry. We guarantee consistent product quality, strong technical services and stable global supply for all customers and partners.